{
  "docId": "019de073-ace7-72fb-abe1-daa413db1006",
  "docSlug": "7bdf7da39a85a072a380631ad1d0379d",
  "documentTitle": "Cabaletta Bio | Investor Presentation Deck | 23 slides",
  "authorId": "cabaletta-bio",
  "authorName": "Cabaletta Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 23,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes detailed scientific citations and specific cohort dosing strategies.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-ace7-72fb-abe1-daa413db1006/16",
  "deckHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006",
  "deckJsonHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006.json",
  "deckAnchorHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.1,
        "y": 0.6
      },
      "kind": "chart",
      "text": "Persistence over time for A4 and A5 cohorts",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f26a8901-425e-4823-973e-cba0142e4e07",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.35,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "DSG3-CAART Persistence to 29d in Cohorts A1-A5",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fe6d8a4-3121-467a-8b21-1b48263dc813",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.55,
        "x": 0.4,
        "y": 0.25
      },
      "kind": "list",
      "text": "Dose-dependent increase in CAART persistence leveled off with cohort A5; CY reduces 'cytokine sink'; Potential reduction in anti-DSG3 autoantibodies; CY & IVIg likely to provide transient improvement; Up to 9 mo post-infusion required.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f4cb71e-5754-4822-a240-1bdebbd51c41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.55,
        "x": 0.4,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Combination sub-study cohort: A4 dose (2.5x10^9 cells) + cyclophosphamide (CY) & IVIg",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c70e3b3b-32a2-46ef-b930-89a0d6dd7167",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.4,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "Cohort A6m | 2x A5 dose (1-1.5x10^10 cells): Two A5 infusions 3 weeks apart to potentially increase the duration of maximal exposure to DSG3-CAART",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc81e997-bf8b-4694-8ee2-61ae4c31162c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "1-8. References to clinical studies and methodology.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "035bb020-b272-42df-9b61-1530804d3cea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Dose-dependent persistence flattens; aim to increase CAART exposure",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78ca6cc2-0edc-47d3-9e2d-351a0ce3ff29",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "evidence-matrix",
      "slug": null,
      "matchId": "d4c75d27-939e-422c-a8ff-a65acc836aed",
      "evidence": "Cites 8 clinical studies to support the proposed combination therapy strategy.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 17,
      "from": 14,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5feb5883-6e1a-454b-a089-f5a12b3713b0",
      "evidence": "Problem statement and traction slides",
      "position": 0,
      "objective": "Highlight limitations of current treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}